DNA Damage and Repair

DNA Damage-Inducible Gene, Reprimo Functions as a Tumor Suppressor and Is Suppressed by Promoter Methylation in Gastric Cancer

Akira Ooki1,2, Keishi Yamashita1, Kensei Yamaguchi2, Anupom Mondal3, Hiroshi Nishimiya1, and Masahiko Watanabe1

Abstract

In several types of human cancer, the gene expression of Reprimo, a highly glycosylated protein, is frequently silenced via methylation of its promoter. The aim of this study was to characterize the epigenetic inactivation of Reprimo and its biologic function and clinical relevance in gastric cancer. The correlation between Reprimo methylation and clinical relevance was assessed in 83 primary human gastric cancer tissues. The effects of Reprimo expression were also examined using in vitro and in vivo assays. Reprimo methylation was cancer specific and frequently observed. In two gastric cancer cell lines without Reprimo methylation, we observed faint or weak Reprimo expression under normal conditions and high expression under DNA-damaging conditions. In four gastric cancer cell lines with Reprimo methylation, however, Reprimo expression remained faint even under DNA-damaging conditions, with expression being restored in combination with agents that induce demethylation. Enforced Reprimo expression robustly inhibited cell proliferation and anchorage-independent colony formation and enhanced DNA damage-induced apoptosis. Inverse effects were observed via siRNA-mediated knockdown of endogenous Reprimo. Reprimo expression inhibited tumorigenesis in vivo. Reprimo methylation was also associated with a poor response in patients with gastric cancer treated with chemotherapy (P1/4 0.028), and a poor prognosis in patients with advanced gastric cancer (P1/4 0.03). In conclusion, Reprimo expression is normally induced in response to DNA damage, acting as a novel tumor suppressor in gastric cancer. However, Reprimo methylation abrogates its expression and effects. The clinical assessment of Reprimo promoter methylation may serve not only as a predictive marker for chemotherapy, but also as a marker for tumor aggressiveness. Mol Cancer Res; 11(11); 1362–74. ©2013 AACR.

Introduction

Gastric cancer remains a major clinical challenge, being both the fourth most common cancer and the second leading cause of cancer-related death worldwide (1). Globally, a total of 989,600 new cases and 738,000 deaths are estimated to have occurred in 2008. The case-fatality ratio of gastric cancer is higher than that of other common malignancies, such as colorectal, breast, or prostate cancer (2). However, although recent improvements in diagnostic tools and methods have facilitated the detection of gastric cancer at an early stage, advanced gastric cancer is still associated with a poor clinical outcome due to the limited success of surgery and chemotherapy.

Accumulating evidence suggests that cancer is caused by both epigenetic and genetic abnormalities (3). The epigenetic pathway involved in the development of cancer is determined by chromatin structure, including DNA methylation, histone modifications, or noncoding regulatory RNAs (4). DNA methylation occurs at the fifth carbon of the cytosine, termed a dinucleotide CpG, which precedes a guanine. When methylation occurs within dinucleotide CpG-rich regions, "CpG islands," of a gene promoter, it is associated with a compact chromatin structure and is accompanied by transcriptional silencing of the affiliated gene, especially tumor-suppressor genes (5). DNA methylation occurs more frequently than genetic mutations in gastric cancer and has recently opened the exciting doors for developing cancer biomarkers and therapeutic targets (6–8).

Reprimo is a highly glycosylated protein localized predominantly in the cytoplasm, which was identified by differential display screening of genes distinctly expressed between X-ray-

Authors' Affiliations: 1Department of Surgery, Kitasato University Hospital, Kitasato, Sagamihara, Kanagawa; 2Department of Gastroenterology; and 3Research Institute for Clinical Oncology, Saitama Cancer Center, Kornuro, Ina Machit, Kita-Adachi-gun, Saitama, Japan

Note: Supplementary data for this article are available at Molecular Cancer Research Online (http://mcr.aacrjournals.org/).

Corresponding Author: Akira Ooki, Department of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Sagamihara 228-8555, Kanagawa, Japan. Phone: 81-42-778-8735; Fax: 81-42-778-8735; E-mail: sp99q9@piano.ocn.ne.jp
doi: 10.1158/1541-7786.MCR-13-0091
©2013 American Association for Cancer Research.
irradiated wild-type and p53-deficient mouse embryonic fibroblast cells (9). Transiently enforced Reprimo expression induces G2 arrest of the cell cycle by inhibiting Cdc2 activity and nuclear translocation of the Cdc2–cyclin B1 complex in various cell lines such as DLD1, HeLa, and MCF7 cells (9), whereas loss of Reprimo expression is associated with an increase in uterine sarcoma incidence in mutant α53 transgenic mice treated with the carcinogen 1,2-dimethylhydrazine (10). These findings suggest that both the expression and function of Reprimo as a tumor-suppressor gene are regulated in a p53-dependent manner. In contrast, Reprimo promoter methylation has been reported to be involved in an alternative mechanism that regulates Reprimo expression in various types of tumors (11–13). Furthermore, the regulation of Reprimo expression is independent of p53 status in neuronal cells treated with copper, with neuronal damage being associated with Wilson disease (14). In gastric cancer, Reprimo promoter methylation is a frequent event as we and others have previously reported (11, 13, 15). The relationship between Reprimo and gastric cancer, however, has never been examined from a mechanistic and functional point of view.

In the present study, we examined the clinical significance of the Reprimo gene, especially for its promoter methylation in primary gastric cancer and assessed the functional change associated with its abnormality.

Materials and Methods

Cell lines and tissue samples

The gastric cancer cell line MKN7 was provided by the Cell Resource Center for Biomedical Research Institute of Development, Aging and Cancer, Tohoku University in December 2006 (Miyagi, Japan). Seven other gastric cancer cell lines (GCIY, AZ521, KatoIII, SH10, H111, MKN74, and NUGC4) were purchased from RIKEN BioResource Center for Biomedical Research Institute of Development, Aging and Cancer, Tohoku University in December 2006 (Miyagi, Japan). Seven other gastric cancer cell lines treated with copper, with neuronal damage being associated with Wilson disease (14). In gastric cancer, Reprimo promoter methylation is a frequent event as we and others have previously reported (11, 13, 15). The relationship between Reprimo and gastric cancer, however, has never been examined from a mechanistic and functional point of view.

In the present study, we examined the clinical significance of the Reprimo gene, especially for its promoter methylation in primary gastric cancer and assessed the functional change associated with its abnormality.

Quantitative methylation-specific PCR

To quantify the methylation level of Reprimo, quantitative methylation-specific PCR (Q-MSP) was conducted via an iQ Supermix (Bio-Rad Laboratories) in triplicate on the iCycler iQ Real-Time PCR Detection System (Bio-Rad Laboratories). Serial dilutions of CpGenome universal methylated DNA (Chemicon International, Inc.) were used to construct the calibration curve for each plate. CpGenome universal methylated DNA and unmethylated DNA (Chemicon) were used as a methylation positive and a negative control, respectively. The methylation value was defined by the ratio of fluorescence intensity emitted from the amplified bisulfite DNA of the CpG islands of Reprimo gene divided by that of β-actin and multiplied by 100 (Q-MSP value). The optimal cutoff value for Q-MSP was determined using a receiver operating characteristic (ROC) curve.

Quantitative reverse transcriptase PCR

Total RNA was isolated using TRIzol Reagent (Invitrogen) in accordance with the manufacturer’s protocol and reverse transcribed with a SuperScript III Reverse Transcriptase kit (Invitrogen). Quantitative reverse transcriptase PCR (qRT-PCR) was conducted to quantify the expression level of Reprimo gene using the iCycler iQ Real-Time PCR Detection System (Bio-Rad). Relative quantitative analysis normalized to β-actin was conducted via the comparative cycle threshold method (19).
5-Aza-2'-deoxycytidine treatment

Cells (1 × 10^6/T-75 flask) were treated with 5 μmol/L of the demethylating agent 5-aza-2'-deoxycytidine (5-Aza-dC; Sigma-Aldrich) dissolved in 50% acetic acid or were mock treated with PBS including the same amount of acetic acid every 24 hours for 5 days (20).

Table 1. Correlation between Reprimo hypermethylation and clinicopathologic variables in patients with gastric cancer

<table>
<thead>
<tr>
<th>Variables</th>
<th>Total number</th>
<th>Hypermethylation of Reprimo promoter</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Negativity N (%)</td>
<td>Positivity N (%)</td>
<td>P</td>
</tr>
<tr>
<td>Age, y</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60</td>
<td>35</td>
<td>15 (43)</td>
<td>20 (57)</td>
<td>NS (0.090)</td>
</tr>
<tr>
<td>≥60</td>
<td>48</td>
<td>11 (23)</td>
<td>37 (77)</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>57</td>
<td>17 (30)</td>
<td>40 (70)</td>
<td>NS (0.854)</td>
</tr>
<tr>
<td>Female</td>
<td>26</td>
<td>9 (35)</td>
<td>17 (65)</td>
<td></td>
</tr>
<tr>
<td>Main location</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper</td>
<td>18</td>
<td>5 (28)</td>
<td>13 (72)</td>
<td>NS (0.097)</td>
</tr>
<tr>
<td>Middle</td>
<td>31</td>
<td>14 (45)</td>
<td>17 (55)</td>
<td></td>
</tr>
<tr>
<td>Lower</td>
<td>34</td>
<td>7 (21)</td>
<td>27 (79)</td>
<td></td>
</tr>
<tr>
<td>Lymphatic invasion</td>
<td></td>
<td></td>
<td></td>
<td>NS (&gt;0.999)</td>
</tr>
<tr>
<td>Absence</td>
<td>15</td>
<td>5 (33)</td>
<td>10 (67)</td>
<td></td>
</tr>
<tr>
<td>Presence</td>
<td>68</td>
<td>21 (31)</td>
<td>47 (69)</td>
<td></td>
</tr>
<tr>
<td>Vascular invasion</td>
<td></td>
<td></td>
<td></td>
<td>NS (0.058)</td>
</tr>
<tr>
<td>Absence</td>
<td>25</td>
<td>12 (48)</td>
<td>13 (52)</td>
<td></td>
</tr>
<tr>
<td>Presence</td>
<td>58</td>
<td>14 (24)</td>
<td>44 (76)</td>
<td></td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
<td></td>
<td>NS (&gt;0.999)</td>
</tr>
<tr>
<td>Well and moderate</td>
<td>33</td>
<td>10 (30)</td>
<td>23 (70)</td>
<td></td>
</tr>
<tr>
<td>Poor</td>
<td>50</td>
<td>16 (32)</td>
<td>34 (68)</td>
<td></td>
</tr>
<tr>
<td>Depth of invasion</td>
<td></td>
<td></td>
<td></td>
<td>NS (0.766)^a</td>
</tr>
<tr>
<td>m and sm</td>
<td>15</td>
<td>4 (27)</td>
<td>11 (73)</td>
<td></td>
</tr>
<tr>
<td>mp and ss</td>
<td>37</td>
<td>12 (32)</td>
<td>25 (68)</td>
<td></td>
</tr>
<tr>
<td>se and si</td>
<td>31</td>
<td>10 (32)</td>
<td>21 (68)</td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
<td></td>
<td>NS (0.480)</td>
</tr>
<tr>
<td>Absence</td>
<td>29</td>
<td>11 (38)</td>
<td>18 (62)</td>
<td></td>
</tr>
<tr>
<td>Presence</td>
<td>54</td>
<td>15 (28)</td>
<td>39 (72)</td>
<td></td>
</tr>
<tr>
<td>Stage according to the AJCC/UICC</td>
<td></td>
<td></td>
<td></td>
<td>NS (0.571)^a</td>
</tr>
<tr>
<td>I (IA and IB)</td>
<td>20</td>
<td>3 (23)</td>
<td>10 (77)</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>20</td>
<td>12 (48)</td>
<td>13 (52)</td>
<td></td>
</tr>
<tr>
<td>III (IIIA and IIIB)</td>
<td>23</td>
<td>5 (20)</td>
<td>20 (80)</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>20</td>
<td>6 (30)</td>
<td>14 (70)</td>
<td></td>
</tr>
<tr>
<td>p53 gene status</td>
<td></td>
<td></td>
<td></td>
<td>NS (0.834)</td>
</tr>
<tr>
<td>Wild-type</td>
<td>54</td>
<td>16 (30)</td>
<td>38 (70)</td>
<td></td>
</tr>
<tr>
<td>Mutation</td>
<td>29</td>
<td>10 (34)</td>
<td>19 (66)</td>
<td></td>
</tr>
<tr>
<td>Response rate (CR and PR)^c</td>
<td></td>
<td></td>
<td></td>
<td>0.028</td>
</tr>
<tr>
<td>Absence</td>
<td>20</td>
<td>5 (25)</td>
<td>15 (75)</td>
<td></td>
</tr>
<tr>
<td>Presence</td>
<td>21</td>
<td>13 (62)</td>
<td>8 (38)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: m, mucosa; sm, submucosa; mp, muscularis propria; ss, subserosa; se, serosa exposed; si, serosa infiltrating; CR, complete response; PR, partial response; NS, not significant.

^aMann–Whitney U test.

^bLog-rank test; the remaining variables, χ² test.

^cAssessment for fluoropyrimidine class and cisplatin treatment.

Western blot analysis

Whole-cell lysates were extracted in radioimmunoprecipitation assay buffer (Pierce) supplemented with 10 μL/mL Halt Protease Inhibitor Cocktail Kit (Pierce) and Halt Phosphatase Inhibitor Cocktail Kit (Pierce). The protein concentrations were determined using a Coomassie Plus-The
Better Bradford Assay Kit (Pierce), separated on NuPAGE® 4% to 12% Bis-Tris Gel (Invitrogen) with anti-flag-V5 mouse monoclonal antibody (Sigma-Aldrich) and anti-β-actin mouse monoclonal antibody (Sigma-Aldrich).

**Plasmid transfection and siRNA transfection**

A full-length complementary DNA (cDNA) of Reprimo was isolated from GCIY cells using PCR with Platinum PfX DNA Polymerase (Invitrogen). The plasmid expressing Reprimo (pcDNA 3.1-Reprimo) was obtained by cloning the PCR products into the pcDNA 3.1 Directional TOPO vector via a pcDNA 3.1 Directional TOPO Expression Kit (Invitrogen). The sequence of the cloned Reprimo cDNA was verified by sequencing analysis, and an empty vector with self-ligation (pcDNA 3.1-mock) was used as a control. Cells were transfected using Lipofectamine 2000 Reagent (Invitrogen) in OPTI-MEM medium (Invitrogen). Stable clones with Reprimo or mock were established by G418 (Invitrogen) selection. For siRNA transfection, cells (2 × 10^5) were seeded in 6-well plates 24 hours before transfection. The cells were transfected with 1 μmol/L Accell SMARTpool, siRNA-Reprimo (Thermo Fisher Scientific) mixed with Accell siRNA Delivery Media (Thermo Fisher Scientific) according to the Thermo Scientific Dharmacco Accell siRNA Delivery Protocol. The Accell Non-targeting Pool (siRNA-ctr) and Accell siRNA Delivery Media alone (siRNA-mock) were used as a control for nonsequence-specific effects and as a mock treatment, respectively.

**Anchorage-independent colony formation assay**

Anchorage-independent cell growth was analyzed by plating 0.36% top agarose (Becto Agar; Becton, Dickinson and Company) containing 1 × 10^5 cells on a surface of 0.72% bottom agarose in the 6-well plates. Cells were fed weekly by overlying fresh soft-agar solution, and colonies were photographed after 2 weeks of incubation. The experiment was carried out in triplicate.

**Proliferation assay and invasion assay**

The effects of Reprimo expression on cell proliferation and viability (2 × 10^5 cells/well) were measured using the Premix WST-1 Cell Proliferation Assay System (Takara Bio, Co.,) in 96-well plates. The invasion assay was conducted in the 24-well BD BioCoat Matrigel Invasion Chamber (BD Biosciences Discovery Labware). Forty-eight hours after transfection, the lower chamber was filled with 750 μL Dulbecco’s modified Eagle medium (DMEM; GibCO) supplemented with 10% FBS as a chemoattractant, and cells (5 × 10^5 /well) were then seeded into an upper chamber in 500 μL of serum-free DMEM. After incubation for 22 hours, the membrane of the upper chamber was fixed and stained using Diff-Quik reagent (Sysmex, Co.,). Cells that had invaded through the membrane were counted in four separated fields per well. Both experiments were carried out in triplicate.

**Cell-cycle and apoptosis assays**

Cell-cycle and apoptosis assays were conducted using the Guava PCA System (Guava Technologies, Inc.,). In the cell-cycle assay, after synchronization for 48 hours in serum-free medium, the cells were then cultured in complete medium. After 24 hours, the cells (2 × 10^5) were then fixed in 75% ethanol, and stained with propidium iodide (Guava Cell Cycle Reagent). In the apoptosis assay, the harvested cells (1 × 10^7) were stained with Annexin V and 7-AAD (Guava Nexin Reagent) for discrimination of early and late apoptotic cells, respectively. Both experiments were carried out in triplicate and analyzed using CytoSoft 2.1.5 software (Guava Technologies).

**Mouse xenograft assay**

Female BALB/cAjl nude mice ages 5 weeks were purchased from CLEA Japan Inc. Mice were subcutaneously injected with AZ521 patient cells or AZ521 stable cells transfected with pcDNA 3.1-Reprimo or pcDNA 3.1-mock on both flanks (2.5 × 10^6 cells per flank). In the treatment combined with CDDP and 5-FU, mice with tumors approximately 5 mm in diameter received intraperitoneal administration of CDDP (0.1 mg/kg) and 5-FU (10 mg/kg) once daily for 7 days (21). Each group consisted of 3 mice (n = 3).

**Statistical analysis**

Categorical variables were analyzed via χ² test or Mann–Whitney U test, and continuous variables were analyzed via Student t test. For continuous variables, the data are expressed as mean ± SD. The disease-specific survival (DSS) was measured from the date of surgery to the date of death or the last follow-up. DSS was estimated via the Kaplan–Meier method, and values were compared using the log-rank test. P < 0.05 was considered to indicate statistical significance. All statistical analyses were conducted with the Statistical Analysis System (SAS) software package (SAS Institute).

**Results**

**Cancer-specific Reprimo promoter methylation in gastric cancer**

The location of CpG islands in the 5′-flanking region of Reprimo genomic sequencing is shown in Fig. 1A. The Reprimo promoter harbors CpG islands encompassing the transcription start site, and we previously reported that Reprimo harbored its promoter methylation in 75% (6/8) of gastric cancer cell lines, 80% (8/10) of primary human gastric cancer tissues, and 10% (1/10) of corresponding normal tissues in the preliminary dataset of 10 matched pairs by bisulfite sequencing analysis (15). Q-MSP can achieve a much more objective and specific assessment of a small amount of genomic DNA through PCR amplification using methylation-specific primers and fluorescent probes (22). Q-MSP analysis was therefore conducted using the same samples (15) to confirm the above findings on bisulfite.
sequencing analysis (Fig. 1B). The Q-MSP value was significantly higher in gastric cancer cell lines (5.25 ± 1.73, \( P = 0.006 \)) or primary human gastric cancer tissues (3.05 ± 0.88, \( P = 0.014 \)) than in the corresponding normal tissues (0.51 ± 0.34). Next, the bisulfite sequencing with cloned PCR products was conducted to assess the correlation between the Q-MSP values and methylation status of the individual CpG sites (Fig. 1C and D). Higher Q-MSP values tended to indicate denser methylation.

We next examined the correlation of Reprimo methylation to clinical relevance using Q-MSP in 83 primary tumors and corresponding normal mucosa tissue specimens with human patients with gastric cancer. The optimal cutoff value for distinguishing between tumor and normal tissues was calculated using a ROC analysis, and the best cutoff value of 0.42 showed a sensitivity of 69% and specificity of 82% (Fig. 2A). Furthermore, all cell lines or human samples with a Q-MSP value higher than 0.42 showed denser methylation on bisulfite sequencing with cloned PCR products (i.e., hypermethylation; Fig. 1D). Reprimo promoter hypermethylation was found in 69% (57/83) of tumor tissues and 18% (15/83) of corresponding normal tissues, with both differences being statistically significant (\( P < 0.0001 \); Fig. 2B). In addition, the Q-MSP values in tumor tissues were significantly higher than those in normal tissues, not only for different tumor stages, but also in individual patients (\( P < 0.0001 \); Fig. 2C). These findings suggest that Reprimo promoter hypermethylation might be a frequent and early
alteration that occurs specifically in the development of cancer. Because some genes show age-related methylation alterations (23), the clinicopathological characteristics of Reprimo promoter hypermethylation were assessed. Although Reprimo promoter methylation was marginally associated with vascular invasion ($P = 0.058$), no correlation was found between Reprimo promoter hypermethylation and clinicopathological factors, including aging and stage of tumor development (Table 1).

Transcriptional silencing by Reprimo promoter methylation

Reprimo was classified as a $p53$-mediated gene in embryonic fibroblast cells (9). However, Reprimo promoter methylation is an alternative mechanism in the regulation of Reprimo expression in various tumor types (11–13). Furthermore, the regulation of Reprimo expression is independent of the $p53$ gene status in neuronal cells treated with copper (14). Reprimo expression was recently reported to be repressed by a ligand-activated estrogen receptor via a mechanism involving histone deacetylase-7 and Fork head A1 in breast cancer (24). Thus, $p53$ gene status is unlikely to be the only determining factor in the regulation of Reprimo expression.

To clarify whether or not promoter methylation or $p53$ gene status results in transcriptional silencing of Reprimo in gastric cancer, the expression level was evaluated by RT-PCR in eight gastric cancer cell lines and the preliminary dataset of five matched pairs (Fig. 3A). In Reprimo promoter methylation, Reprimo mRNA expression was undetectable in four of the six gastric cancer cell lines, all four tumor tissues, ...
Figure 3. DNA damage-inducible Reprimo expression and its silencing by promoter methylation. A, expression level of Reprimo by RT-PCR (top) and qRT-PCR (Reprimo/β-actin × 1,000, bottom) in eight gastric cancer cell lines and preliminary dataset. B, expression level of Reprimo after genotoxic stress in SH10 cells without Reprimo methylation by RT-PCR (top) or qRT-PCR (bottom), SH10 cells were incubated for 24 hours followed by UV irradiation (10 mJ/cm²). Cells were treated with 5-FU (10 µmol/L) or CDDP (20 µmol/L) for 24 hours. With mock treatment cells as 1.0, the relative expression level of Reprimo was shown by qRT-PCR. C, expression level after treatment with demethylating agent 5-Aza-dC alone or in the presence or absence of UV irradiation by qRT-PCR. Cells were treated with 5-Aza-dC (5 µmol/L) for 5 days. When combined with the UV irradiation, UV irradiation was conducted on Day 4 of 5-Aza-dC treatment. 5-Aza, 5-Aza-dC; m, mock including the same volume of acetic acid; *, P < 0.05; Error bars; SD. N, human normal mucosa; T, human primary tumor; W, p53 wild-type; M, p53 mutation.

and one of the corresponding normal tissues by RT-PCR. Furthermore, similar results were observed with qRT-PCR. Reprimo promoter methylation showed a trend toward the decreased expression, whereas Reprimo expression was undetectable even in SH10 cells without methylation. Next, we examined the correlation between p53 gene status and Reprimo expression. The mutation of p53 was documented in 34.9% (29/83) of tumor tissues, which were missense mutations clustered in the core DNA-binding domain (residues 94–312; ref. 25) and have been documented as biologically inactive via the transcriptional activity on the WAF1 promoter in the Universal Mutation Database TP53 mutation databases (26; Supplementary Table S2). Reprimo promoter methylation was unrelated to p53 gene status (Table 1).

Given that Reprimo expression was induced by X-ray irradiation as the DNA damage in embryonic fibroblast cells with p53 wild-type (9), we examined whether or not Reprimo expression was altered in response to forms of genotoxic stress, such as UV irradiation, 5-FU (fluoropyrimidine class), or CDDP (platinum-based class). SH10 cells without...
Reprimo methylation increased Reprimo expression under DNA-damaging conditions despite the presence of the p53 mutation (Fig. 3B), speculating that DNA damage-inducible Reprimo expression may be abrogated because of methylation of the Reprimo promoter in a p53-independent manner. To substantiate this hypothesis, six cell lines with different p53 gene and Reprimo methylation statuses were treated with the demethylating agent 5-Aza-dC in the presence or absence of DNA-damaging agents (Fig. 3C). In GCIY cells without Reprimo promoter methylation, Reprimo expression was weak under normal conditions, but was induced by UV irradiation despite the presence of p53 mutation, in line with findings in SH10 cells. On the other hand, in four cell lines (AZ521, NUGC, KatoIII, and MKN74 cells) with Reprimo promoter methylation, the expression of Reprimo could be slightly restored by demethylation alone, but not UV irradiation. Notably, in combination with demethylation and UV irradiation, these cell lines were restored regardless of p53 gene status. Similar trends were also observed in the treatment with 5-FU or CDDP (data not shown). We examined Reprimo mutations via direct sequencing analysis using primer sequences including the entire open reading frame according to the previous study (13) in eight gastric cancer cell lines and 83 primary tumors, and no mutations were found (data not shown).

Tumor-suppressive activity after transfection of Reprimo
Transcriptional silencing of Reprimo due to its frequent promoter methylation prompted investigation into the potential role of Reprimo as a tumor-suppressor gene in gastric cancer. AZ521 cells with methylation were stably transfected with pcDNA 3.1-Reprimo containing the full-length cDNA of Reprimo gene (Fig. 4A). The AZ521 cells transfected with pcDNA 3.1-ExpiReprimo (AZ-r10 and AZ-r16 cells) resulted in an increase of mRNA levels, unlike those with pcDNA 3.1-mock (AZ-mock cells). Reprimo protein levels were also confirmed by Western blotting using an anti-fl-V5 antibody. An important characteristic in the growth of aggressive cancer cells is the ability of cancer cells to grow under anchorage-independent conditions. We therefore examined tumors, whether or not the exogenous expression of Reprimo could suppress the growth of cells in soft agar. The AZ-r10 and AZ-r16 cells showed significantly decreased cell size and colony number (Fig. 4B), but no decrease in Matrigel invasive ability (Supplementary Fig. S2A) when compared with AZ-m cells. We also observed a decrease in cellular proliferation under normal conditions or CDDP exposure in AZ-r10 and AZ-r16 cells (Fig. 4C).

Reprimo has been shown able to act as a G2 phase cell-cycle break in cell lines such as DLD1, HeLa, and MCF7 cells (9), but not in LBT2 and GH3 pituitary cells (27), indicating that it may have different functions depending on the type of cell. To examine the role of Reprimo in regulating cell growth in gastric cancer, a cell-cycle assay was conducted (Supplementary Fig. S2B). Analysis of the cell-cycle distribution showed a significantly increased sub-G1 population along with minimally affected S and G2–M populations in AZ-r10 and AZ-r16 cells. H111 cells transfected with pcDNA 3.1-Reprimo also showed similar results. To verify these results, an apoptosis assay was conducted under exposure to the DNA-damaging agents 5-FU or CDDP (Fig. 4D). Both early and late apoptosis were significantly enhanced in AZ-r10 and AZ-r16 cells compared with AZ-m cells.

To further confirm the tumor-suppressive activity of Reprimo, knockdown of endogenous Reprimo was conducted using siRNA. SH10 cells without methylation were transfected with siRNA-Reprimo (SH-si cells) or siRNA-ctr (SH-ctr cells). SH-si cells, but not SH-ctr cells, resulted in decreased Reprimo expression induced by CDDP exposure when compared with mock treatment cells (Fig. 4E) and showed a dramatic repression of 5-FU or CDDP-mediated apoptosis (Fig. 4F). We observed similar results in GCIY cells (data not shown).

Tumor-suppressive activity of Reprimo in mouse xenograft assay
To examine the effect of Reprimo on tumorigenesis in vivo, AZ521 patient (AZ-p), AZ-m, AZ-r10, or AZ-r16 cells were subcutaneously injected into both flanks of nude mice. A remarkable reduction of tumor volume was observed in mice injected with Reprimo-transfected cells (AZ-r10 or AZ-r16 cells) when compared with AZ-p or AZ-m cells (Fig. 5A and B). Tumor weight was also significantly decreased in mice injected with AZ-r10 or AZ-r16 cells (Fig. 5C). As Reprimo promoter methylation was marginally associated with vascular invasion in 83 patients with gastric cancer (Table 1), angiogenesis, visualized as a marked red color with the formation of a dense surrounding vascular network, was more greatly observed in the tumors of mice injected with AZ-p or AZ-m cells than those injected with AZ-r10 or AZ-r16 cells (Fig. 5D).

To examine the anticancer effect of treatment combined with CDDP and 5-FU via Reprimo expression in vivo, mice with tumors approximately 5 mm in diameter received intraperitoneal administration of CDDP and 5-FU for 7 days. No anticancer effect was observed in mice injected with AZ-p or AZ-m cells, but an anticancer effect was observed in the mice injected with AZ-r10 or AZ-r16 cells (Supplementary Fig. S3).

Potential use of Reprimo methylation as a predictive marker
The most promising candidate epigenetic marker reported thus far for the prediction of responses to chemotherapy is O6-methylguanine-methyltransferase (MGMT). MGMT reverses the addition of alkyl groups to the guanine base of DNA and protects DNA damage caused by the alkylating agents, such as temozolomide, thus generating chemoresistance. Therefore, the methylation of MGMT is a predictor of a favorable response to temozolomide in gliomas (28). In the present study, we found that Reprimo could enhance 5-FU or CDDP-mediated apoptosis in gastric cancer. The combination of CDDP and fluoropyrimidine class, including 5-FU, capecitabine, or S-1, was the most standard regimen of...
Figure 4. Tumor-suppressive activity of Reprimo. A, expression level of Reprimo in AZ521 cells transfected with pcDNA 3.1-mock or pcDNA 3.1-Reprimo. The stable cells were established by G418 selection after transfection with pcDNA 3.1-Reprimo (AZ-r10 or r16). (Legend continued on the following page.)
chemotherapy against gastric cancer (29, 30). We therefore analyzed 83 human gastric cancer samples to evaluate whether or not the assessment of Reprimo methylation could be a predictive marker for chemotherapy combined with CDDP and fluoropyrimidine class. Of the 49 patients who received a combination regimen for metastatic or advanced gastric cancer (79), we identified 29 patients with advanced gastric cancer who received a combination regimen for metastatic or advanced gastric cancer (79), we identified 29 patients with advanced gastric cancer who received a combination regimen for metastatic or advanced gastric cancer (79), we identified 29 patients with advanced gastric cancer who received a combination regimen for metastatic or advanced gastric cancer (79), we identified 29 patients with advanced gastric cancer who received a combination regimen for metastatic or advanced gastric cancer (79). Among these patients, we found that negative methylation (22) in the Reprimo promoter was associated with improved patient outcomes. These findings suggest that Reprimo methylation status could be a prognostic marker for patients with advanced gastric cancer who receive a combination regimen of CDDP and fluoropyrimidines.

Figure 5. Effect of Reprimo expression on tumorigenesis in vivo and Kaplan–Meier analysis in patients with advanced gastric cancer. A, mouse xenograft assay. AZ-p, AZ-m, AZ-r10, or AZ-r16 cells were subcutaneously injected into both flanks of nude mice (2.5 × 10^6 cells per flank), respectively. Twenty-eight days after injection, mice were sacrificed, and pictures were taken. B, time course of tumor growth. Tumor volumes were calculated from measurements of two orthogonal diameters (larger (x) and smaller (y) diameters) using the following formula: volume = xy^2/2. * P < 0.05; Error bars; SD; NS, not significant. C, tumor weight in mice injected with Reprimo-transfected cells (AZ-r10 or AZ-r16 cells) when compared with AZ-p or AZ-m cells. * P < 0.05; Error bars; SD; NS, not significant. D, typical appearance of tumors excised on day 28. Angiogenesis was visualized as a marked red color with the formation of a dense surrounding vascular network. E, Kaplan–Meier analysis in 41 patients who received a combination regimen (CDDP and fluoropyrimidine class). F, Kaplan–Meier analysis in 68 patients with advanced gastric cancer.
recurrent gastric cancer, 41 had measurable lesions. The tumor response was assessed according to Response Evaluation Criteria in Solid Tumors, version 1.1 (31). Reprimo promoter hypermethylation, previously defined as a value more than 0.42 on Q-MSP, was inversely associated with the response rate \( P = 0.028 \) (Table 1), and showed a trend toward a worsening prognosis, compared with absence of Reprimo promoter methylation (Fig. 5E).

We next examined whether or not the assessment of Reprimo hypermethylation could be used to predict patient prognosis and thereby serve as a marker for tumor aggressiveness in 68 patients with advanced gastric cancer. Reprimo promoter hypermethylation had a significantly poor outcome \( P = 0.031 \); Fig. 5F). In multivariate analysis, Reprimo promoter hypermethylation was independently associated with a poor prognosis, with a HR of 2.148 \( P = 0.026 \); Supplementary Table S3).

Discussion

We previously reported that Reprimo promoter methylation was one of the most frequent cancer-specific alterations, using bisulfite sequencing analysis in primary gastric cancer tissues (15). Of note, many of the methylation alterations are tissue specific or associated with the field of cancerization, but are not cancer specific (32). As such, we examined the epigenetic inactivation, biologic function, and clinical relevance in gastric cancer in the present study.

In gastric cancer cell lines without Reprimo promoter methylation, we observed an unexpectedly faint or weak Reprimo expression under normal conditions but a robust expression under DNA-damaging conditions. In gastric cancer cell lines with Reprimo promoter methylation, however, we observed faint expression even under DNA-damaging conditions, with expression being restored only in combination with the demethylating agent. In 83 human gastric cancer samples, Reprimo promoter methylation was a cancer-specific alteration that frequently occurred at an early stage in the development of cancer and was not related to \( p53 \) status. Thus, Reprimo promoter methylation may be the predominant mechanism for loss of DNA damage-inducible Reprimo expression, regardless of \( p53 \) status.

Although promoter methylation alterations are common events in human cancers, most are merely passengers that have no effect per se on the process of carcinogenesis. In contrast, driver methylation mainly inactivates tumor-suppressive activity, leading to the processes of tumor initiation, progression, or metastasis. Thus, the identification of driver methylation will be of key importance for cancer etiology, development of biomarkers, and therapeutic targets (33). Enforced Reprimo expression robustly inhibited tumor cell growth, including cell proliferation and anchorage-independent colony formation. In addition, the cell-cycle distribution showed a significantly increased sub-G1 population, but not G2 arrest that has been reported as a function of Reprimo (9). Our findings are in line with those in pituitary tumors (27), and Reprimo may therefore have differential roles depending on the type of tumor. Apoptosis assays also showed that enforced Reprimo expression enhanced DNA damage-induced apoptosis, indicating that Reprimo might suppress cell growth through the induction of apoptosis but not cell-cycle arrest in gastric cancer. Inverse effects were observed on siRNA-mediated knockdown of endogenous Reprimo. Furthermore, Reprimo expression inhibited tumorigenesis in a mouse xenograft model. Taken together, these findings suggest that Reprimo possesses bona fide tumor-suppressive activity, and its methylation may be a driver methylation in gastric cancer. Further investigation of the Reprimo-regulated molecules is required to clarify the mechanisms by which Reprimo exerts tumor-suppressive activity.

Three major clinical oncology areas can potentially benefit from DNA methylation-based biomarkers: cancer detection, tumor prognosis, and prediction of treatment responses (34). The cancer-specific Reprimo promoter methylation that occurs at an early stage in disease development can serve as a potential biomarker for early detection in gastric cancer. Indeed, Reprimo promoter methylation was frequently detected in plasma from patients with gastric cancer (11). Furthermore, Reprimo promoter methylation is significantly lower in chemoradiotherapy responders than in nonresponders in esophageal cancer (35), and is predictive of a poor prognosis in pancreatic ductal carcinoma (36). Reprimo promoter methylation was inversely associated with response to the treatment combined with CDDP and the fluoropyrimidine class as a standard chemotherapy. In addition, Reprimo expression enhanced CDDP or 5-FU–mediated apoptosis in vitro, and anticancer effect of treatment combined with CDDP and 5-FU in vivo. We were unable to assess any association between Reprimo protein level and response to chemotherapy due to lack of a commercially available antibody. However, Reprimo expression is induced by DNA damage, and as such, potential functionality of Reprimo as tumor-suppressive activity may not be reflected by expression level of mRNA or protein at diagnosis. At present, the assessment of Reprimo promoter methylation may be useful in predicting response to chemotherapy with CDDP and the fluoropyrimidine class. Furthermore, Reprimo promoter methylation in patients with advanced gastric cancer was an independent prognostic factor reflecting an aggressive tumor phenotype, indicating that Reprimo promoter methylation is one of the most critical alterations in cancer progression and is also a potential marker for tumor aggressiveness.

In the last decade, a number of landmark trials have shown efficacy of multimodality therapy in resectable gastric cancer, such as perioperative chemotherapy (37), adjuvant chemoradiotherapy (38), adjuvant chemotherapy (39, 40), and neoadjuvant chemoradiotherapy (41). However, the therapeutic strategies by which clinicians distinguish between the various treatment options remain a contentious issue. One point of clinical importance is that, although preoperative therapy has the potential to improve the therapeutic outcome for responders (42), it runs the risk of shifting the status of nonresponders from potentially resectable to unresectable, despite that radical resection is the only curative
treatment modality, requiring the predictive marker for treatment response. Therefore, information on Reprimo promoter methylation may provide much needed guidance in determining the therapeutic strategies, such as the selection of the most suitable patients for preoperative therapy in gastric cancer.

In conclusion, Reprimo expression is normally induced in response to DNA damage, robustly inhibiting tumorgenesis through enhancing apoptosis as a novel tumor suppressor in gastric cancer. Methylation of the Reprimo promoter is a frequent and cancer-specific event that abrogates its expression and functions in p53-independent manner. In addition, clinical assessment of Reprimo promoter methylation may serve not only as a predictive marker for chemotherapy consisting of CDDP and the fluoropyrimidine class, but also as a marker for tumor aggressiveness. Further research will be necessary to validate the clinical potential of Reprimo promoter methylation as a biomarker in gastric cancer.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

References


Disclaimer
The funding agencies had no role in the design of the study, data collection, analysis, interpretation of the results, preparation of the manuscript, or in the decision to submit the manuscript for publication.

Authors’ Contributions
Conception and design: A. Ooki, K. Yamashita, M. Watanabe
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A. Ooki, K. Mondal, H. Nishimuya, M. Watanabe
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A. Ooki, K. Yamashita, M. Watanabe
Writing, review, and/or revision of the manuscript: A. Ooki, K. Yamashita, K. Yamaguchi, M. Watanabe
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): K. Yamashita, M. Watanabe
Study supervision: K. Yamashita, M. Watanabe

Grant Support
This work was supported, in part, by the Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan and by the Japanese Foundation for Multidisciplinary Treatment of Cancer.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received February 21, 2013; revised July 8, 2013; accepted July 23, 2013; published OnlineFirst August 27, 2013.


Molecular Cancer Research

DNA Damage-Inducible Gene, Reprimo Functions as a Tumor Suppressor and Is Suppressed by Promoter Methylation in Gastric Cancer

Akira Ooki, Keishi Yamashita, Kensei Yamaguchi, et al.


Updated version  Access the most recent version of this article at: doi:10.1158/1541-7786.MCR-13-0091

Supplementary Material  Access the most recent supplemental material at: http://mcr.aacrjournals.org/content/suppl/2013/09/04/1541-7786.MCR-13-0091.DC1

Cited articles  This article cites 42 articles, 12 of which you can access for free at: http://mcr.aacrjournals.org/content/11/11/1362.full.html#ref-list-1

Citing articles  This article has been cited by 1 HighWire-hosted articles. Access the articles at: /content/11/11/1362.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.